Actively Recruiting
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
Led by Erasmus Medical Center · Updated on 2024-04-22
150
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting data from patients with metastatic prostate cancer who are receiving Lutetium-PSMA (Lu-PSMA) therapy. The study aims to gather real-world information on how effective and safe this treatment is, as well as to collect dosimetry and biomarker data. This will help identify which patients benefit most from Lu-PSMA therapy. The study involves collecting blood samples during routine clinical visits to analyze circulating tumor DNA (ctDNA) and circulating tumor cells. These samples, along with PSMA-PET scans, will be used to evaluate response to treatment and explore biomarkers. There is no intervention beyond standard care; the study is observational and focuses on data collection. Participants will be monitored for up to 44 months to assess overall survival and progression-free survival. Researchers will also study the heterogeneity of PSMA positivity, the effect of biomarkers on treatment response, and scan data. The study is sponsored by Erasmus Medical Center and involves regular clinical follow-ups and blood draws as part of routine care.
CONDITIONS
Brief Title
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants should be at least 18 years old.
- Participants should be able to understand the written information and be able to provide informed consent.
- Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 44 months
Participants who undergo routine care are observed. Blood samples are collected during routine visits to analyze circulating tumor DNA and circulating tumor cells.
Visits aligned with routine clinical care
Trial Site Locations
Total: 1 location
1
Erasmus MC
Rotterdam, South Holland, Netherlands, 3015 CN
Actively Recruiting
Research Team
S
Stijn Koolen, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here